JO3370B1 - طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 - Google Patents

طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Info

Publication number
JO3370B1
JO3370B1 JOP/2012/0332A JOP20120332A JO3370B1 JO 3370 B1 JO3370 B1 JO 3370B1 JO P20120332 A JOP20120332 A JO P20120332A JO 3370 B1 JO3370 B1 JO 3370B1
Authority
JO
Jordan
Prior art keywords
antagonist
methods
tumor growth
antagonizing
receptor
Prior art date
Application number
JOP/2012/0332A
Other languages
English (en)
Inventor
Zhang Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3370B1 publication Critical patent/JO3370B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي توفير طرق لتثبيط أو توهين نمو الورم في مريض بواسطة إعطاء IL-6 الى مريض. في نماذج محددة ، يتم استخدام طرق الاختراع لتثبيط نمو الورم المقاوم لمضاد VEGF في مريض. يمكن أن يكون مضاد IL-6، على سبيل المثال، عبارة عن جسم مضاد يرتبط نوعيا بـ IL-6R. يمكن إعطاء مضاد IL-6 بالاشتراك مع مضاد VEGF، و/أو مضاد EGFR، و/أو مضاد ErbB3.
JOP/2012/0332A 2011-11-10 2012-11-04 طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 JO3370B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US201261613538P 2012-03-21 2012-03-21

Publications (1)

Publication Number Publication Date
JO3370B1 true JO3370B1 (ar) 2019-03-13

Family

ID=47179020

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0332A JO3370B1 (ar) 2011-11-10 2012-11-04 طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Country Status (20)

Country Link
US (3) US20130122003A1 (ar)
EP (1) EP2776468B1 (ar)
JP (3) JP6144689B2 (ar)
KR (1) KR101718748B1 (ar)
CN (1) CN103930443B (ar)
AR (1) AR088671A1 (ar)
AU (2) AU2012335596B2 (ar)
BR (1) BR112014011211A2 (ar)
CA (1) CA2853836C (ar)
IL (2) IL231854A (ar)
IN (1) IN2014CN02923A (ar)
JO (1) JO3370B1 (ar)
MX (1) MX357837B (ar)
MY (1) MY163953A (ar)
RU (1) RU2648150C2 (ar)
SG (1) SG11201401286QA (ar)
TW (3) TW201716776A (ar)
UY (1) UY34444A (ar)
WO (1) WO2013071016A2 (ar)
ZA (1) ZA201402414B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
JP7100425B2 (ja) * 2014-06-28 2022-07-13 コディアック サイエンシーズ インコーポレイテッド デュアルｐｄｇｆ／ｖｅｇｆアンタゴニスト
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
JP2018516263A (ja) * 2015-05-29 2018-06-21 メリマック ファーマシューティカルズ インコーポレーティッド 癌併用療法
NZ783685A (en) 2015-12-30 2025-09-26 Kodiak Sciences Inc Antibodies and conjugates thereof
CN110402097A (zh) 2016-12-07 2019-11-01 普罗根尼蒂公司 胃肠道检测方法、装置和系统
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
SG11202008242XA (en) * 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
US11965176B2 (en) 2018-03-14 2024-04-23 Hunan Siweikang Therapeutics Co. Ltd Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
AU2020205951A1 (en) * 2019-01-07 2021-07-22 Hunan Siweikang Therapeutics Co. Ltd Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
MX2023009956A (es) * 2021-02-27 2023-09-05 Eluminex Biosciences Suzhou Ltd Proteinas de fusion de anticuerpos dirigidas al receptor de il-6 y factores angiogenicos.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
DE69525971T3 (de) 1994-12-29 2013-01-10 Chugai Seiyaku K.K. Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CA2376379C (en) * 1999-06-08 2007-08-07 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2001027116A2 (en) 1999-10-07 2001-04-19 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
WO2002036164A1 (en) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
DK1673397T3 (da) * 2003-07-02 2011-03-07 Univ Genova Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
US20070134242A1 (en) 2003-10-17 2007-06-14 Chugai Seiyaku Kabushiki Kaisha Mesothelioma therapeutic agent
KR20080084818A (ko) 2005-11-25 2008-09-19 각고호우징 게이오기주크 전립선암 치료제
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
SI2041177T1 (sl) * 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
EP2376126B1 (en) * 2008-11-25 2017-12-20 AlderBio Holdings LLC Antagonists of il-6 to prevent or treat thrombosis
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Also Published As

Publication number Publication date
MY163953A (en) 2017-11-15
WO2013071016A2 (en) 2013-05-16
US20170022279A1 (en) 2017-01-26
TW201716776A (zh) 2017-05-16
IL248620A0 (en) 2016-12-29
TW201806620A (zh) 2018-03-01
JP2014534237A (ja) 2014-12-18
JP6283754B2 (ja) 2018-02-21
WO2013071016A3 (en) 2013-07-25
CA2853836A1 (en) 2013-05-16
IL231854A0 (en) 2014-05-28
CN103930443B (zh) 2017-08-04
ZA201402414B (en) 2015-03-25
AU2012335596A1 (en) 2014-05-22
CN103930443A (zh) 2014-07-16
IL231854A (en) 2016-11-30
TWI604852B (zh) 2017-11-11
EP2776468B1 (en) 2018-01-24
RU2014118739A (ru) 2015-12-20
UY34444A (es) 2013-05-31
US20130122003A1 (en) 2013-05-16
KR20140095481A (ko) 2014-08-01
EP2776468A2 (en) 2014-09-17
KR101718748B1 (ko) 2017-03-22
IN2014CN02923A (ar) 2015-07-03
MX2014004886A (es) 2014-07-09
TW201332569A (zh) 2013-08-16
US20140322215A1 (en) 2014-10-30
SG11201401286QA (en) 2014-05-29
MX357837B (es) 2018-07-26
CA2853836C (en) 2019-07-23
BR112014011211A2 (pt) 2017-04-25
RU2648150C2 (ru) 2018-03-22
JP2017095489A (ja) 2017-06-01
US9409990B2 (en) 2016-08-09
AU2012335596B2 (en) 2018-05-17
AR088671A1 (es) 2014-06-25
AU2018203666A1 (en) 2018-06-14
JP6144689B2 (ja) 2017-06-07
JP2018083841A (ja) 2018-05-31

Similar Documents

Publication Publication Date Title
JO3370B1 (ar) طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX363193B (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX380220B (es) Composiciones farmacéuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofílica.
MX343227B (es) Anticuerpos anti-erbb3.
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
IN2014DN09098A (ar)
UA107827C2 (xx) Антитіло до cd40
EP4219552A3 (en) Il-11r binding proteins and uses thereof
WO2012071561A3 (en) Anti-il-6 antibodies for the treatment of anemia
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
SG194701A1 (en) Anti-cd40 antibodies and methods of use
NZ707086A (en) Anti-cd40 antibodies and methods of use
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX360774B (es) Antagonistas de progesterona.
MX2015005928A (es) Metodos para tratar el cancer de ovario con antagonistas de dll4.
BR112014014824A2 (pt) anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos
MX2016007947A (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con caracteristicas melancolicas.
WO2018102670A3 (en) Method of treating cancer and method of sensitizing cancer cells to the action of chemotherapeutic agents via growth hormone receptor antagonists or knock down